Trial · NCT03388632
Results by group100
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 100
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) at Which Dose-Limiting Toxicities (DLT) Occurred With rhIL-15 Administered in Combination With Fixed Doses of Nivolumab and Ipilimumab | All Participants in Escalation Phase of Arm C | 1.0 | mcg/kg/day | ||
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm A Doublet A - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Nivolumab 240mg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm A/Arm A1 Doublet A - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Nivolumab 240mg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm B Doublet B - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 1-Recombinant Human Interleukin(rHIL-15) 0.5mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 2-Recombinant Human Interleukin(rHIL-15) 1mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 3-Recombinant Human Interleukin(rHIL-15) 2mcg/kg & Nivolumab 240mg/Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 3/Triplet 2/Recombinant Human Interleukin 2mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C/Arm C1 Triplet 1 - Recombinant Human Interleukin 0.5mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C/Arm C1 Triplet 2-Recombinant Human Interleukin 1mcg/kg & Nivolumab 240mg/Ipilimumab 1mg/kg | Possibly related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm A Doublet A - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Nivolumab 240mg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm A/Arm A1 Doublet A - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Nivolumab 240mg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm B Doublet B - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 1-Recombinant Human Interleukin(rHIL-15) 0.5mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 2-Recombinant Human Interleukin(rHIL-15) 1mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 3-Recombinant Human Interleukin(rHIL-15) 2mcg/kg & Nivolumab 240mg/Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C Triplet 3/Triplet 2/Recombinant Human Interleukin 2mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C/Arm C1 Triplet 1 - Recombinant Human Interleukin 0.5mcg/kg/Nivolumab 240mg/Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm C/Arm C1 Triplet 2-Recombinant Human Interleukin 1mcg/kg & Nivolumab 240mg/Ipilimumab 1mg/kg | Probably related to rh IL-15 | 0 | toxicities | |
| Number of Dose-limiting Toxicities (DLT) Possibly, Probably, or Definitely Related to Study Drugs | Arm A Doublet A - Recombinant Human Interleukin (rH IL-15) 0.5mcg/kg & Nivolumab 240mg | Definitely related to rh IL-15 | 0 | toxicities |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03388632/results